Tumour cells apoptosis factor - Immune System Key Ltd

Drug Profile

Tumour cells apoptosis factor - Immune System Key Ltd

Alternative Names: 84AA–API 14AA; Nerofe

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune System Key
  • Class Antineoplastics; Cardiovascular therapies; Peptide hormones
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Interleukin 1 receptor-like 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I Solid tumours
  • Discontinued Myocardial infarction

Most Recent Events

  • 04 Jul 2018 Phase-I development for Solid tumours is ongoing Israel(NCT01690741)
  • 01 Jul 2018 Phase-II clinical trials in Acute myeloid leukaemia (Combination therapy) in Israel (IV) (NCT03059615)
  • 01 Jul 2018 Phase-II clinical trials in Acute myeloid leukaemia (Monotherapy) in Israel (IV) (NCT03059615)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top